Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

The recent jump in share price (Dec. '11-Current) has no basis in reality and seems fueled only by investors given to hoping for the best and low volume days allowing an easy path for pumping prices temporarily. To borrow words from so many market pundits it is the picture of "irrational exuberance."

Simply shorting the 25% spike in Progenics Pharmaceuticals, INC on the phase III data for it's constipation drug. ZZlangerhans has more info at his pitch:
http://caps.fool.com/Pitch/PGNX/6096863/progenics-has-jumped-nearly-50.aspx?source=itxsittb0000001

Even if this gets into approval, I don't see much market upside. Short term call.

Piggy back off Z's analysis.

Progenics has jumped nearly 50% in two weeks from their baseline of 5 without a precipitating catalyst, and I smell stirrapulation. The 60M upfront payment from Salix for Relistor was a gift, but that's old news now and the company will surely eat up that cash. Relistor won't be bringing in much revenue even with expanded approval in April 2012, and the PSMA vaccine has been pickling in phase I for at least four years already. At least the company had the good taste to drop their sham virology program.

currently 100 shares in my portfolio.

CEO buying shares on regular basis

John Paul Pick ask Ray

If PGNX can't find a new partner for RELISTOR this year, it will face some difficulty with finance.

Upcoming Catalyst

Red Raider is Lord

Lord knows

biotech plays that zzlangerhans is behind on & picks that the CAPs community agrees with via star rating.
GREENthumb: ARNA, PGNX, ARRY, GENZ, CEPH, CPD, MYGN, ELN
REDthumb: PLX, ITMN, CLDA, PCYC

I need help. I think this company will do well based on they look like they are at a low point, but will bounce back. If someone would like to let me know why I am right or wrong I would apprecaite it.

Go Bio!

Speculative but possible cancer effect from pain drug.

Its basically cash rich, has a few good products waiting to be launched once a partner is found for marketing, and its current stock price is an all time low, which can't get any worse than this.

Great

EXCELLENT PIPELINE, NO DEBT, GOOD MANAGEMENT

Down on no news - owned this through FDA and EMEA approvals but then sold out - back now since it's at the same levels again but closer to profitability and/or buyout (Wyeth?)